Search fresh public links, source activity, and ready-to-use post angles for Epicutaneous Immunotherapy (Epit).
Fresh curated links around Epicutaneous Immunotherapy (EPIT) are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
DBV Technologies will submit its Viaskin Peanut FDA application in late 2026 after agreeing to include additional safety data. The post FDA Agreement Clears Regulatory Path for Via...
A microneedle stamp worn for just a few minutes each day to treat peanut allergies has begun clinical trials. The post Moonlight Therapeutics Launches First Clinical Trial of Micro...
Lycia's experimental therapy removes IgE instead of blocking it and is expected to enter Phase 1 clinical testing soon. The post Lycia’s Experimental Therapy Introduces a New Way t...
Ascendant-221 uses a dual-action anti-IgE approach that could offer longer-lasting protection against severe allergic reactions. The post New Biologic Aims to Provide Long-Lasting...
DBV Technologies has screened the first participant in a pioneering trial of its peanut allergy patch for infants. The post DBV Launches Peanut Patch Study in Infants as Young as S...
Novel nanoparticle-based peanut allergy therapy produced encouraging immune responses in Phase 1 and now advances toward larger clinical trials. The post Spanish Biotech Reports En...
Johns Hopkins study finds omalizumab delivers clinical trial-like results in helping patients safely introduce allergenic foods. The post Real-World Study Confirms Omalizumab Helps...
Israeli scientists developed a modified peanut that showed promising results in treating children with severe peanut allergies. The post Researchers Develop Novel Treatment by Unfo...
Ask your doctor about neffy (epinephrine nasal spray) today.
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
Researchers developed regulatory T cells armed with chimeric allergen receptors—CAlleR Tregs—which in tests reduced or preventing asthma symptoms in mice sensitized to a birch tree...
A groundbreaking advancement in the treatment of severe asthma has emerged from the recent findings of the Phase 3 SUNRISE clinical trial. This pivotal study has demonstrated that...
In a stunning immunological twist, researchers have borrowed a page from the cancer-fighting playbook to devise a living drug that could snuff out allergic asthma at its roots. Ins...
New EAACI survey data show strong support for nasal epinephrine and persistent barriers to autoinjector adherence. The post Patients and Physicians Prefer Epinephrine Nasal Spray O...
Atopic dermatitis (AD), the most common form of eczema, impacts patients' life trajectories beyond the physical scars. A novel study shows that adults with AD, particularly those...
CHICAGO — Dupilumab significantly improved esophageal distensibility and diameter in eosinophilic esophagitis at 24 weeks, alongside marked gains in endoscopic and histologic disea...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.